{"title": "Alle | BioNTech", "author": null, "url": null, "hostname": null, "description": "The Investor Relations website contains information about BioNTech's business for stockholders, potential investors, and financial analysts.", "sitename": "BioNTech", "date": "2023-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Statement zu von Moderna eingereichtem Patentrechtsstreit Read more about Statement zu von Moderna eingereichtem Patentrechtsstreit", "language": null, "image": null, "pagetype": "Website", "links": ["#main-menu", "https://www.biontech.com/int/en/home.html", "https://www.biontech.com/de/de/home/newsroom.html", "/de/investors-media", "https://pro.biontech.de/de/public/login.html?destination=/content/probiontech/de/de/home", "/taxonomy/term/4016?mobile=1&page=6", "/de/taxonomy/term/4016?mobile=1&page=6", "https://www.biontech.com/de/de/home/connect.html?chatbotFullscreen=true", "https://www.biontech.com/int/en/home.html", "/de/news/press-releases", "/de/events-presentations", "/de/financials-filings/sec-filings", "/de/financials-filings/annual-reports", "/de/financials-filings/quarterly-reports", "/de/financials-filings/financial-calendar", "/de/corporate-governance/overview", "/de/encrypted-node/13041", "/de/esg", "/de/stock-information/stock-quote-chart", "/de/stock-information/analyst-coverage", "/de/stock-information/shareholder-fraud-warning", "/de/encrypted-node/12006", "/de/stock-information/information-dividend", "/de/stock-information/investor-faqs", "/de/agm/agm-2023", "/de/agm/agm-archive", "/de/contact-us", "https://www.biontech.com/de/de/home/newsroom.html", "/de/investors-media", "https://pro.biontech.de/de/public/login.html?destination=/content/probiontech/de/de/home", "/de", "/de/news-releases/news-release-details/statement-zu-von-moderna-eingereichtem-patentrechtsstreit", "/de/news-releases/news-release-details/statement-zu-von-moderna-eingereichtem-patentrechtsstreit", "/de/news-releases/news-release-details/pfizer-und-biontech-geben-update-zur-wirksamkeit-ihres-covid-19", "/de/news-releases/news-release-details/pfizer-und-biontech-geben-update-zur-wirksamkeit-ihres-covid-19", "/de/news-releases/news-release-details/pfizer-und-biontech-reichen-antrag-fuer-notfallzulassung-eines", "/de/news-releases/news-release-details/pfizer-und-biontech-reichen-antrag-fuer-notfallzulassung-eines", "/de/news-releases/news-release-details/biontech-veroeffentlicht-ergebnisse-des-zweiten-quartals-2022", "/de/news-releases/news-release-details/biontech-veroeffentlicht-ergebnisse-des-zweiten-quartals-2022", "/de/news-releases/news-release-details/biontech-und-genmab-erweitern-globale-strategische-kollaboration", "/de/news-releases/news-release-details/biontech-und-genmab-erweitern-globale-strategische-kollaboration", "/de/news-releases/news-release-details/pfizer-und-biontech-treiben-covid-19-impfstoffstrategie-weiter", "/de/news-releases/news-release-details/pfizer-und-biontech-treiben-covid-19-impfstoffstrategie-weiter", "/de/news-releases/news-release-details/biontech-veroeffentlicht-am-8-august-2022-ergebnisse-des-zweiten", "/de/news-releases/news-release-details/biontech-veroeffentlicht-am-8-august-2022-ergebnisse-des-zweiten", "/de/news-releases/news-release-details/pfizer-und-biontech-schliessen-einreichung-des-omikron-ba1", "/de/news-releases/news-release-details/pfizer-und-biontech-schliessen-einreichung-des-omikron-ba1", "/de/news-releases/news-release-details/statement-zu-patentrechtsstreit-deutschland", "/de/news-releases/news-release-details/statement-zu-patentrechtsstreit-deutschland", "/de/news-releases/news-release-details/pfizer-und-biontech-schliessen-neue-liefervereinbarung-mit-der", "/de/news-releases/news-release-details/pfizer-und-biontech-schliessen-neue-liefervereinbarung-mit-der", "/de/taxonomy/term/4016?mobile=1&page=5", "/de/taxonomy/term/4016?mobile=1&page=7", "https://investors.biontech.de/de/taxonomy/term/4016/feed?mobile=1", "https://www.biontech.com/int/en/home.html", "tel:004961319084", "mailto:service@biontech.de", "https://www.biontech.com/de/de/home/about/who-we-are/vision-and-mission.html", "https://www.biontech.com/de/de/home/research-and-innovation/our-approach.html", "https://www.biontech.com/de/de/home/pipeline-and-products/pipeline.html", "https://www.biontech.com/de/de/home/manufacturing-and-services/production-network.html", "https://www.biontech.com/de/de/home/careers/working-at-biontech.html", "https://www.biontech.com/de/de/home/covid-19/covid-19-portal.html", "https://www.biontech.com/de/de/home/newsroom.html", "/de/investors-media", "https://pro.biontech.de/de/public/login.html?destination=/content/probiontech/de/de/home", "https://www.biontech.com/de/de/home/connect.html", "https://www.biontech.com/de/de/home/terms-of-use.html", "https://www.biontech.com/de/de/home/general-terms-and-conditions.html", "https://www.biontech.com/de/de/home/general-conditions-of-purchase.html", "https://www.biontech.com/de/de/home/data-privacy-statement.html", "https://www.biontech.com/de/de/home/data-processing-terms-business-partners.html", "https://formulare.pro.biontech.de/DE/forms/medinfo", "https://www.biontech.com/de/de/home/imprint.html", null, "https://twitter.com/BioNTech_Group", "https://www.linkedin.com/company/biontech-se/"]}